Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017 through the close of Roche’s (NASDAQ:RHHBY) acquisition of FMI in August 2018. He currently serves as a member of the Board of Directors for Tang Therapeutics, Vinetic, Singular Genomics, Adaptive Biotechnologies, Octave Health, the Personalized Medicine Coalition, and the Mission Hospital Foundation (Provident/St. Joseph Health). As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health). Dr. Pellini  received a BA from Boston College, an MBA from Drexel University and am MD from Jefferson Medical College.